KBC Group NV Has $462,000 Holdings in Encompass Health Corporation (NYSE:EHC)

KBC Group NV lifted its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 6.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,557 shares of the company’s stock after purchasing an additional 263 shares during the period. KBC Group NV’s holdings in Encompass Health were worth $462,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Colonial Trust Co SC bought a new position in Encompass Health during the fourth quarter worth $29,000. Transce3nd LLC bought a new position in Encompass Health during the fourth quarter worth $40,000. CBIZ Investment Advisory Services LLC raised its stake in Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after buying an additional 127 shares during the last quarter. Signaturefd LLC raised its stake in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company’s stock worth $65,000 after buying an additional 125 shares during the last quarter. Finally, Johnson Financial Group Inc. bought a new position in Encompass Health during the fourth quarter worth $72,000. Institutional investors own 97.25% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Stephens raised shares of Encompass Health from an “overweight” rating to a “strong-buy” rating and set a $135.00 target price for the company in a research note on Thursday, June 5th. Truist Financial restated a “buy” rating and issued a $135.00 price target (up from $116.00) on shares of Encompass Health in a report on Monday, April 28th. KeyCorp raised their price target on shares of Encompass Health from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Tuesday, May 27th. Wall Street Zen cut shares of Encompass Health from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Finally, Barclays raised their price target on shares of Encompass Health from $118.00 to $129.00 and gave the stock an “overweight” rating in a report on Friday, April 25th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $127.00.

Encompass Health Stock Up 0.1%

EHC opened at $119.04 on Friday. Encompass Health Corporation has a fifty-two week low of $82.74 and a fifty-two week high of $123.13. The firm has a market capitalization of $12.00 billion, a P/E ratio of 24.60, a PEG ratio of 2.42 and a beta of 0.88. The company’s 50-day moving average is $119.39 and its 200 day moving average is $105.37. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.06 and a quick ratio of 1.06.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. Encompass Health had a net margin of 8.97% and a return on equity of 17.63%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the previous year, the company earned $1.12 earnings per share. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. Research analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.57%. The ex-dividend date is Tuesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is presently 14.05%.

Insider Buying and Selling

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of Encompass Health stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the sale, the insider owned 11,958 shares of the company’s stock, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the sale, the chief executive officer directly owned 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is owned by insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.